key: cord-0730268-4vji0yfa
authors: Amer, Yasser S.; Titi, Maher A.; Godah, Mohammad Wefqy; Wahabi, Hayfaa A.; Hneiny, Layal; Abouelkheir, Manal Mohamed; Hamad, Muddathir H.; ElGohary, Ghada Metwally; Hamouda, Mohamed Ben; Ouertatani, Hella; Velasquez-Salazar, Pamela; Acosta-Reyes, Jorge; Alhabib, Samia M.; Esmaeil, Samia Ahmed; Fedorowicz, Zbys; Zhang, Ailing; Chen, Zhe; Lipttrott, Sarah Jane; Frungillo, Niccolò; Jamal, Amr A.; Almustanyir, Sami A.; Dieyi, Newman Ugochukwu; Powell, John; Hon, Katrina J.; Alzeidan, Rasmieh; Azzo, Majduldeen; Zambrano-Rico, Sara; Ramirez-Jaramillo, Paulina; Florez, Ivan D.
title: International alliance and AGREE-ment of 71 clinical practice guidelines on the management of critical care patients with COVID-19: a living systematic review
date: 2021-11-14
journal: J Clin Epidemiol
DOI: 10.1016/j.jclinepi.2021.11.010
sha: 7cc1297f5424c1d6ca121f586828c297207fedf7
doc_id: 730268
cord_uid: 4vji0yfa

OBJECTIVE: We aimed to systematically identify and critically assess the clinical practice guidelines (CPGs) for the management of critically ill patients with COVID-19 with the AGREE II instrument. STUDY DESIGN AND SETTING: We searched Medline, CINAHL, EMBASE, CNKI, CBM, WanFang, and grey literature from November 2019 to November 2020. We did not apply language restrictions. One reviewer independently screened the retrieved titles and abstracts, and a second reviewer confirmed the decisions. Full texts were assessed independently and in duplicate. Disagreements were resolved by consensus. We included any guideline that provided recommendations on the management of critically ill patients with COVID-19. Data extraction was performed independently and in duplicate by two reviewers. We descriptively summarized CPGs characteristics. We assessed the quality with the AGREE II instrument and we summarized relevant therapeutic interventions. RESULTS: we retrieved 3,907 records and 71 CPGs were included. Means (Standard Deviations) of the scores for the six domains of the AGREE II instrument were 65%(SD19.56%), 39%(SD19.64%), 27%(SD19.48%), 70%(SD15.74%), 26%(SD18.49%), 42%(SD34.91) for the scope and purpose, stakeholder involvement, rigor of development, clarity of presentation, applicability, editorial independence domains, respectively. Most of the CPGs showed a low overall quality (less than 40%). CONCLUSION: Future CPGs for COVID-19 need to rely, for their development, on standard evidence-based methods and tools.

people. 3 The COVID-19 global pandemic has spread to over 200 countries with devastating impacts on public health, patients, healthcare workers, health systems, social life, and economies. These consequences are even more evident in low-and middle-income countries. 4, 5 Although most COVID-19 cases recover without any major complications, some patients develop a progressive disease due to pneumonia and respiratory failure. 6 These patients are managed in Intensive Care Units (ICUs) and have high mortality rates, ranging between 25-40%. 7 Given the extraordinary burden that the pandemic has created on the emergency and critical care units worldwide, there is an urgent need for evidence-based guidance to facilitate optimal clinical and policy decision-making.

Clinical Practice Guidelines (CPGs) are organized clinical statements designed to assist practitioners with health care decision-making and have been identified as effective tools for improving the quality of patient care by informing clinicians, and other stakeholders. [8] [9] [10] However, high-quality CPGs are methodologically complex to develop, and they are time-consuming. This makes them incompatible with emergency situations. Rapid Guidelines (RGs) are defined as CPGs which are completed in a 1-to 3-months' timeframe are alternatives to full CPGs to provide guidance in response to an emergency [11] [12] [13] . Given the magnitude of the COVID-19 pandemic it was not surprising that a multitude of RGs were developed to inform healthcare professionals and decision-makers on the best management for patients with COVID-19. Although RGs need to follow methodological shortcuts to expedite RG development, there are key methodological elements that need to be met, even in the context of emergencies. Thus, RGs' developers need to find an appropriate balance between rigor and speed without undermining their trustworthiness.

The Appraisal of Guidelines for REsearch and Evaluation tool (AGREE II) is the most widely utilized tool to appraise the quality of CPGs, and it has been considered as the 'gold standard' for CPG quality assessment. 14, 15 Although, not specific for assessing RGs, AGREE II is a good blueprint of the minimum standards to consider a CPG as trustworthy.

The authors of this review, known as the 'COVID-19 Guidelines Review Collaborative Group' (COVID-GRG), is a global group of CPG's experts and developers who aim at systematically reviewing and appraising the recently published CPGs for COVID-19. Furthermore, the COVID-RGCG developed a partnership with the COVID-Evidence Network to support evidence-based decision-making (COVID-END) initiative (https://www.mcmasterforum.org/networks/covid-end) to regularly assess the quality of COVID-19 related evidence-based guidance, that can be useful for clinicians developers and stakeholders interested in finding high-quality evidence-based recommendations that will be used or adapted in their contexts.

Four previous reviews have assessed the quality of COVID-19 CPGs. , [16] [17] [18] . Two of them focused on the CPGs produced in the early phase of the pandemic. Zhao et al evaluated CPGs for five different viruses, including SARS-CoV2, that have caused public health emergencies of international concern over 20 years, with search date ending 2 nd February 2020. Dagens 18 However, an assessment of all the CPGs focused on the management of critically ill COVID -19 patients was lacking. We, therefore, aimed to systematically identify the CPGs for the management of critically ill patients with COVID-19, and critically assess their quality for both clinical and methodological purposes. The clinical purpose was to inform the target users in selecting and using trustworthy CPGs in their daily practice. The methodological purpose was to inform and inspire the progress of standardization of the RG development methodologies. Considering the rapid evolution of the pandemic, the unprecedented and extraordinary volume and speed of the evidence production with COVID-19 and the need for rapid evidence synthesis and guidance, the concept of "living reviews" and "living guidance" became relevant more than ever 19 . We, therefore, considered that this project should have been framed under the same methodology to maintain a living resource that could be used by CPG users, implementers and decision-makers.

This rapid and living systematic review was informed by three methodological guides for CPGs' systematic reviews, rapid reviews, and living reviews 8, 19, 20 . This review is part of a larger extensive review of all CPGs for people with COVID-19. The larger study was registered in the PROSPERO register (https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020179872) 20 . Our review was registered as a traditional systematic review of CPGs but given the rapid evolution of the pandemic and the speed of the evidence synthesis, we thought that a living review would have been more appropriate and useful for decision-makers and CPGs users and implementers.

For inclusion, CPGs had to provide specific recommendations for clinical management, diagnosis and/or treatment of critically ill patients with COVID-19. When more than one version was available, we included only the most updated version or edition of the eligible RGs. Embase to text words and relevant index terms. A search strategy was developed using the keywords that cover all the possible terms and synonyms for COVID-19 and the CPGs. Grey literature search (e.g., CPG databases and repositories and official websites of relevant critical care or intensive care professional societies as a part of snowballing) was conducted across more than 20 different resources and was extended until 30 th of November 2020. Search strategies are described in the (Supplementary material). No language restrictions were applied at the outset.

One reviewer independently screened the retrieved titles and abstracts. A second reviewer screened the undecided and included for quality control. After the first screening, two reviewers screened the full text independently, and a third reviewer was invited to resolve disagreements. All screening and data extraction were conducted by importing the search results into an EndNote Library (version X9) and Google Sheets. We extracted the following variables from each eligible CPG: ID (acronym or first author), country, economic classification, healthcare system, scope of the CPG, language, methods of development, date of publication, developer organization (if applicable), type of organization, target critical disease (specialty), CPG implementation tools, consideration of patients' views and preferences, the use of specific method to assess quality of the evidence (e.g. GRADE), and all options of therapeutic interventions for critically ill people with COVID-19 whether general supportive care or specific COVID-19 therapy, results of the AGREE II quality assessments (See next section). The variables were extracted to an online Google sheet then later presented in tabular formats that were agreed upon after several online focus group discussion and brainstorming meetings with 2-4 reviewers as needed to reach final agreements.

Two reviewers conducted independent quality assessment of each eligible CPG with the AGREE II instrument, which consists of 23 items grouped in six domains, in addition to two final overall assessments. The six AGREE II domains are scope and purpose, stakeholder involvement, rigour of development, clarity of presentation, applicability, and editorial independence. The scope and purpose domain is concerned with the overall aim of the CPG, the specific health questions, and the target population; the stakeholder involvement domain focuses on the extent to which the CPG was developed by the appropriate stakeholders and represents the views of its intended users; the rigour of development domains relates to the process used to gather and synthesize the evidence, the methods to formulate the recommendations, and to update them; the clarity of presentation deals with the language, structure, and format of the CPG; the applicability domain pertains to the likely barriers and facilitators to implementation, strategies to improve uptake, and resource implications of applying the CPG; and the editorial independence domain is concerned with the formulation of recommendations not being unduly biased with competing interests.

A final overall assessment includes the rating of the overall quality of the CPG (OA1) and whether the CPG would be recommended for use in practice (OA2). Despite using only two appraisers meets the minimum standard for AGREE II, it potentially may reduce the reliability of results and increases the likelihood that between-rater variability may directly affect the results. The reviewers held discussions after completing the AGREE II assessments to avoid such variability or discrepancies. We used the online platform MY AGREE PLUS (https://www.agreetrust.org/my-agree/) to run the appraisals. 14, 15 The scoring or rating of each CPG was performed using a seven-point Likert scale and a comments section. Discrepancies in the scoring were resolved by focus group discussions facilitated by a CPG methodologist (YSA). The standardized domain score would be 0% if each appraiser scored 1 for all the items included in this domain (https://www.agreetrust.org/resourcecentre/agree-ii/). 14, 15 

We summarized the general characteristics of the CPGs with descriptive statistics. We present frequencies and proportions to summarize categorical variables used to describe the guidelines. We used mean and standard deviation (SD) to summarize the scores across all the guidelines per domain. The health care system classification was based on Böhm et al 22 , the economic country classification was based on the World Bank (https://data.worldbank.org/country).

For defining a high quality CPG we used the AGREE II domain scores. AGREE II lacks a clear cut-off to distinguish between high-and low-quality CPGs. Several cut-offs that range from 50-80% have been used 23 , but there is not appropriate evidence to determine that one cut-off is better than the other.

We selected a cut-off for high quality CPGs of 60% or more for all the six AGREE II domains in consideration of the limitations associated with the RGs' development. Moreover, the cut-offs for low and moderate quality are <40% and 40%-60%, respectively. For the overall quality of any CPG, whenever there was a discrepancy between OA1 and the mean score for all domains, we relied on the quality of the domain 3 score to upgrade or downgrade the overall score (Tables 2 and 3) .

Furthermore, we compared the clinical content of the eligible CPGs through a tabular summary of therapeutic interventions that were mentioned in the CPGs' recommendation.

For our living systematic review approach for CPGs, the start of the regular review and update process will be launched after the publication of this first review version. We plan monthly surveillance of the databases to identify new guidelines and start the quality assessment of the included guidelines. In common agreement with the Editorial Office, we will provide regular updates, every three months, for at least one more year after the publication with new guidelines assessment.

We identified 3,676 records from databases and 231 from grey literature. We screened 2,486 references and excluded, 2,093 that were not relevant, i.e., they were not guidelines but other type of publications. We reviewed 393 documents in full text and excluded 322 of them with reasons.

Seventy-one CPGs were included, 45 were published in English, seven in Chinese, seven in Italian, five in Spanish, five in German, and two in French. 24-95 Figure 1 displays the selection process through the PRISMA statement flow diagram 21. and we did not identify CPGs from low-income countries. The included CPGs were developed by 74 specialized professional national or international organizations (or societies) in different disciplines that were mostly relevant to critical care or pulmonology. Only 30(42%) CPGs reported their development methodology of which ten (14%) utilized a formal method for assessment of the quality of evidence. Most of the CPGs provided one or more CPG implementation tools (e.g., clinical algorithms, pathways, educational material, mobile apps, patient information guides, among others) (n=46, 65%). Patients' values and preferences, and resources use considerations were considered in 11 CPGs (16%). (Table 1a ).

Despite the fact that a number of eligible retrieved CPG documents were published as RGs, by time we observed that many of them either evolved into or were released at the outset as formal CPGs.

The AGREE II standardized domain ratings are summarized in Table 3 . 48, 49, 51, 53, 57, 59, 63, 69, 71, 74, 76, 79, [81] [82] [83] [84] 88, 95 Overall assessment

The AGREE II standardized domain scores for the first overall assessment (OA1) had a mean of 43% (SD 20.82%). Fourteen CPGs (20%) scored greater than 60%. 26, 31, 35, [47] [48] [49] [50] [51] 59, 60, 67, 68, 83, 84 The authors relied on the ratings of domain 3 as the basis for classification of the quality of the specific CPG (Table 2 and Table 3 ).

The second (overall) assessment (or recommending the use of the CPG in practice) revealed a consensus agreement between the reviewers on (i) recommending the use of three ( CPGs (49%), there was no consensus between the appraisers on the final recommendation.

The scope of the recommendations was variable. Regarding general supportive care, fluid therapy, vasoactive agents, supplemental oxygen therapy, extracorporeal membrane oxygenation, tracheostomy, invasive mechanical ventilation, and critical care management of pain, sedation, and delirium were addressed in 17(24%), 13(18%), 26(51%), 19(27%), 13(18%), 38(54%), and 13(18%) CPGs, respectively. Almost one third of CPGs (n=19-21, 27-30%) addressed specific therapies such as systemic corticosteroids and antiviral agents (e.g., remdesivir, lopinavir/ritonavir, or others). Almost a quarter of them 17 (24%) addressed empiric antimicrobials. Table 2 describes the scope of the recommendations and CPGs categorized according to their evaluated quality.

We assessed 71 CPGs for the management of critically ill COVID-19 patients. Almost half of the CPGs were of poor methodological quality, and only three, were of acceptable quality to recommend their use. 26,35,84 Only four CPGs scored higher than 60% in domain 3 35, 59, 68, 83 . This is concerning because domain 3 defines how rigorous were methods applied, and therefore, it is a key element in defining the trustworthiness of a CPG. A possible explanation might be the extreme conditions under which these CPGs were developed including global uncertainty about the natural history of the COVID-19

infection, the lack of direct evidence, and external pressures to produce rapid advice, lack of technical capacity to develop high-quality CPGs, among others. Moreover, the continuously evolving evidence landscape of COVID-19 would require an ongoing process of monitoring and updating as some recommendations are likely to change. 96 that an CPG can be developed in a rapid timeframe maintaining the highest methodological standards. Although the AGREE II tool was developed to assess "conventional" CPGs, we consider the tool is useful to assess CPGs developed in short timeframes, which has been shown in previous publications. In the review by Kowalski et al, for instance, 46 rapid guidelines developed by WHO and NICE were assessed and obtained average scores of 71% and 81% in the rigor of development domain. 10 .

It has been suggested that Domains 3 (rigour of development) and 5 (applicability), in addition to domain 6 (editorial independence) may have the strongest influence on the results of the two overall assessments. 97, 98 Some discrepancies remained after the discussions between the 23 items, the first and second overall assessments for some CPG appraisals. A limitation that was recognized earlier in a published online survey that proposed including an explicit a priori weighting of the AGREE II items and domains that should have the strongest influence on the two overall assessments. 23 A positive sign of improvement in the CPG development methodology was the application of GRADE in some of the CPGs, unlike the CPGs appraised by Dagens et al. 1 Although GRADE requires more development and capacity, its implementation certainly improves quality and therefore, the trustworthiness. In fact, applying the highest standard methods for developing guidance is even more important in times of crisis 99,100. Some methodological guidance has been developed to support the development of CPGs developed in a short timeframe. For instance, the evaluation of the experiences from developers of RG developed under public health emergencies 101 , has been used to develop GIN-McMaster RG checkist 12 . This checklist provides practical points to consider when there is a need to develop RGs without compromising rigour. 12, 81 Additional resources can also help in this endeavour, including the WHO RG development manual 102 and the Guidelines-International-Network Accelerated Guidelines Development group resources (https://g-i-n.net/working-groups/accelereated-RG-development).

However, we acknowledge that further methodological research is needed to provide better guidance on RGs development. recommendations. Therefore, our team is committed to continue collaborating with these initiatives.

We could not assess temporal changes in the quality of CPGs in comparison to the earlier recent reviews 1,16-17 due to the difference in our identified patient population, in addition to lack of the crude item and domain scores of included CPGs in those reviews. Nevertheless, Kow et al identified multiple inconsistencies across CPGs for the management of critically ill COVID-19 patients especially in comparison with the WHO. 104 Our results will be helpful for healthcare professionals, CPG developers, CPG users/implementers, and decision-makers. Intensive care clinicians now have a summary of the available CPG and can choose among them the most trustworthy to follow. Developers and decision-makers can also choose from our list the CPGs that are of higher quality to eventually adapt or endorse a CPGto be used in their contexts.

Our work has several strengths. We conducted a comprehensive search the most important databases, and we did not apply any language restrictions. Also, we applied the most accepted tool for assessing the quality of the CPGs, the AGREE II instrument, by two experienced and trained reviewers for each CPG. Moreover, this is the first living systematic review of CPGs on COVID or on any disease. Our team is continuously monitoring the available CPGs, and we will update the CPGs' list, and we will continuously assess the new CPGs and re-assess CPGs that may update or improve their methods. We are planning an update of our last search and new CPGs assessment in the following months and update this review version accordingly. However, this study is not free of limitations. We had to exclude, for now, CPGs that were written in languages that were not covered by our research team (i.e., Japanese). Moreover, the assessments were conducted only on CPGs that were either published in peer review journals or posted in official websites as CPG full documents, without considering unpublished or supplementary material, therefore, it is possible that some information was missing to inform the quality of the CPGs in this iteration but it is planned to be covered in the following series of this living review.

In conclusion, our living review found that most of the available CPGs developed to inform the management of critically ill patients with COVID-19 are of low quality. We created a list of recommended CPGs and have described the most important topics and recommendations that they cover so this could be helpful for clinicians and decision-makers interested in the management of these patients.

YSA led the project, overseeing the screening, data extraction, and quality assessment of CPGs, and writing the first draft of the manuscript with input from IDF. YSA and IDF conceptualized the study, 

Additional records identified through other sources (grey literature) (n = 231)

Records after duplicates removed (n = 2486)

Full-text articles assessed for eligibility (n = 393)

Full-text articles excluded, with reasons (n = 322)

These reasons included reviews, clinical research, public health guidelines, social care guidelines, nonguidelines, interpretation of guidelines, advice of COVID-19, case reports, nonguidelines of COVID-19, COVID-19 practice guidelines not targeting critically ill patients, or guidelines published before 2020

Documents included in the AGREE II Appraisal (n = 71)

Scope, quality, and inclusivity of clinical guidelines produced early in the covid-19 pandemic: rapid review. bmj

WHO Director-General's opening remarks at the media briefing on COVID-19 -11

COVID-19) Dashboard

The COVID-19 Pandemic: Effects on Low-and Middle-Income Countries

Learning opportunities from COVID-19 and future effects on health care system

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Mortality rates of patients with COVID-19 in the intensive care unit: a systematic review of the emerging literature

Systematic reviews of clinical practice guidelines: a methodological guide

Improving patient care: the implementation of change in health care

World Health Organization. WHO Handbook for Guideline Development. Geneva: WHO

Development of rapid Guidelines: 1. Systematic survey of current practices and methods. Health research policy and systems

Using GRADE to respond to health questions with different levels of urgency

Development of rapid Guidelines: 3. GIN-McMaster Guideline Development Checklist extension for rapid recommendations. Health Research Policy and Systems

What to do with all the AGREEs? The AGREE portfolio of tools to support the guideline enterprise

Zitzelsberger L on behalf of the AGREE Next Steps Consortium. AGREE II: Advancing guideline development, reporting and evaluation in healthcare

A quality evaluation of guidelines on five different viruses causing public health emergencies of international concern

Systematic review of international guidelines for tracheostomy in COVID-19 patients

Management in the paediatric wards facing the novel coronavirus infection: a rapid review of Guidelines and consensuses

Living systematic reviews: an emerging opportunity to narrow the evidence-practice gap

Rapid reviews to strengthen health policy and systems: a practical guide. Geneva: World Health Organization

Answering the global call for action in rapid practice guidelines for the management of people with the novel Coronavirus COVID-19: protocol for a rapid systematic review

Diagnosis and treatment recommendation for pediatric

Rome: Italian Society for Clinical Nutrition and Metabolism (SINuC)/ Italian Society of Anesthesia, Analgesia, Intensive Care and Intensive Care (SIAARTI); 2020 [cited 23

Guía para el cuidado crítico de pacientes adultos graves con Coronavirus (COVID-19) en las Américas (Versión larga) -OPS/OMS | Organización Panamericana de la Salud

Anesthetic Management of Endovascular Treatment of Acute Ischemic Stroke During COVID-19 Pandemic

European Society of Minimally Invasive Neurological Therapy (ESMINT) and American Association of Neurological Surgeons (AANS) and Congress of Neurological Surgeons (CNS) Cerebrovascular Section

Tracheostomy during SARS-CoV-2 pandemic: Recommendations from the New York Head and Neck Society

Neuroanesthesia Practice During the COVID-19 Pandemic: Recommendations from Society for Neuroscience in Anesthesiology and Critical Care (SNACC)

European Society of Trauma and Emergency Surgery (ESTES) recommendations for trauma and emergency surgery preparation during times of COVID-19 infection

Pediatric Airway Management in COVID-19 Patients: Consensus Guidelines From the Society for Pediatric Anesthesia's Pediatric Difficult Intubation Collaborative and the Canadian Pediatric Anesthesia Society

Recommendation of a practical guideline for safe tracheostomy during the COVID-19 pandemic. European archives of oto-rhino-laryngology: official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS): affiliated with the German Society for Oto-Rhino-Laryngology -Head and Neck

Clinical Consensus Recommendations Regarding Non-Invasive Respiratory Support in the Adult Patient with Acute Respiratory Failure Secondary to SARS-CoV-2 infection

Guidance -Paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS)

Ministry of Health. 21-Airway Management in COVID-19 patient guidelines. Riyadh: Ministry of Health

22-Mechanical Ventilation Protocol for COVID-19. Riyadh: Ministry of Health, Kingdom of Saudi Arabia

Treatment of patients with nonsevere and severe coronavirus disease 2019: an evidence-based guideline

Clinical Management of COVID-19: Interim Guidance. Geneva: WHO, 2020

COVID-19 position statement: Prevention of circuit thrombosis in adult inpatients who are COVID-19 positive and undergoing renal replacement therapy (RRT) on critical care wards: Scottish Government

European Society of Cardiology. ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic

European archives of oto-rhino-laryngology: official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology -Head and Neck Surgery

Prevention, detection and management of VTE in patients with COVID-19 -ICM Anaesthesia COVID-19

ICM Anaesthesia

Clinical guide for the management of critical care for adults with COVID-19 -ICM Anaesthesia COVID-19

ICM Anaesthesia

Interim Guidance for Basic and Advanced Life Support in Adults, Children, and Neonates With Suspected or Confirmed COVID-19

COVID-19 | Guida clinico-pratica a cura del Gruppo Giovani Fadoi | FADOI • Società Scientifica di Medicina Interna

Préconisations pour l'adaptation de l'offre de soins en anesthésie-réanimation dans le contexte de pandémie de COVID-19 / Version Juillet-Août 2020 -La SFAR

The Saudi critical care society (SCCS) clinical practice guidelines on the management of COVID-19 patients in the intensive care unit

Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum

Management of adult cardiac arrest in the COVID-19 era: consensus statement from the Australasian College for Emergency Medicine

Practice recommendations for the management of children with suspected or proven COVID-19 infections from the Paediatric Mechanical Ventilation Consensus Conference (PEMVECC) and the section Respiratory Failure from the European Society for Paediatric and Neonatal Intensive Care (ESPNIC), a consensus statement. European Society for Paediatric and Neonatal Intensive Care

SEDAR-SEMICYUC consensus recommendations on the management of haemostasis disorders in severely ill patients with COVID-19 infection

Remdesivir for severe covid-19: a clinical practice guideline. bmj

Extracorporeal Life Support Organization Coronavirus Disease 2019 Interim Guidelines: A Consensus Document from an International Group of Interdisciplinary Extracorporeal Membrane Oxygenation Providers

Guide de prise en charge des séquelles respiratoires post infection à SARS-CoV-2. Propositions de prise en charge élaborées par la Société de Pneumologie de Langue Française. Version du 10 novembre 2020 [Guide for management of patients with possible respiratory sequelae after a SARS-CoV-2 pneumonia. Support proposals developed by the French-speaking Respiratory Medicine Society. Version of 10

Empfehlungen zur intensivmedizinischen Therapie von Patienten mit COVID-19 [Guideline: Recommendations for intensive care therapy of patients with COVID-19

Recommendations for intensive care therapy for patients with COVID-19

Peri-operative and critical care concerns in coronavirus pandemic. Indian journal of anaesthesia

Coagulopathy and COVID-19. Recommendations for a changing reality

Recommendations for antibacterial therapy in adults with COVID-19-an evidence based guideline

Management of the airway and lung isolation for thoracic surgery during the COVID-19 pandemic

Gastrointestinal bleeding prophylaxis for critically ill patients: a clinical practice guideline

Prevention and treatment of COVID-19-associated hypercoagulability: Recommendations of the Algerian society of transfusion and hemobiology

the Pediatric/Neonatal Hemostasis and Thrombosis Subcommittee of the ISTH SSC. Consensus-based clinical recommendations and research priorities for anticoagulant thromboprophylaxis in children hospitalized for COVID-19-related illness

American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 1

COVID-19 PICU guidelines: for high-and limited-resource settings

Practice Implications for Acute Ischemic Stroke during the COVID-19 Pandemic for the Indian Scenario: Realistic and Achievable Recommendations by the Society of Neurocritical Care (SNCC)

Geburtshilfliche Anästhesie während der SARS-CoV-2-Pandemie: Übersicht der Handlungsempfehlungen [Obstetric Anesthesia During the SARS-CoV-2 Pandemic -a Brief Overview of Published Recommendations for Action by National and International Specialist Societies and Committees

Use of Tracheostomy During the COVID-19 Pandemic: American College of Chest Physicians/American Association for Bronchology and Interventional Pulmonology/Association of Interventional Pulmonology Program Directors Expert Panel Report

la Sociedad Española de Otorrinolaringología y Cirugía de Cabeza y Cuello (SEORL-CCC) y la Sociedad Española de Anestesiología y Reanimación (SEDAR) sobre la traqueotomía en pacientes con COVID-19

Spanish Society of Anesthesiology and Resuscitation (SEDAR) on tracheotomy in patients with COVID-19 infection

Spanish

Behandlungsempfehlungen zur Beatmung von COVID-19-Patienten

Epub ahead of print

Recommendations for Thrombosis Prophylaxis in SARS-CoV-2 (COVID-19)

Gabrielli D; a nome dell'Area Malattie del Circolo Polmonare ANMCO. Position paper ANMCO: Malattie del circolo polmonare e COVID-19

Caring for Critically Ill Children With Suspected or Proven Coronavirus Disease 2019 Infection: Recommendations by the Scientific Sections' Collaborative of the European Society of Pediatric and Neonatal Intensive Care. Pediatric critical care medicine

Current status of global research on novel coronavirus disease (Covid-19): A bibliometric analysis and knowledge mapping

Current status of global research on novel coronavirus disease (COVID-19): a bibliometric analysis and knowledge mapping [version 1

Guideline appraisal with AGREE II: systematic review of the current evidence on how users handle the 2 overall assessments

Guideline appraisal with AGREE II: online survey of the potential influence of AGREE II items on overall assessment of guideline quality and recommendation for use. BMC health services research

Using GRADE in situations of emergencies and urgencies: Certainty in evidence and recommendations matters during the COVID-19 pandemic, now more than ever and no matter what

Evidence-based medicine in times of crisis

*The overall quality of the included rapid guidelines (RGs) was based on a score 60% in D3 (AGREE II Domain 3, rigour of development, rating) per each guideline.

The table summarizes the scope of the recommendations. Each row shows the most common interventions of interest in critical patients with COVID-19 (general supportive care and therapeutic interventions). The second column displays the number of guidelines that cover each recommendation, and the following columns describes the guidelines that provide recommendations for each intervention of interest categorized as Low, Moderate or High quality according to AGREE score obtained in domain 3.